Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib

Leukemia

Volumn 24, Issue 6, 2010, Pages 1230-1233

  Biagi, C ^a   Astolfi, A ^a   Masetti, R ^a   Serravalle, S ^a   Franzoni, M ^a   Chiarini, F ^a   Melchionda, F ^a   Pession, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD7 ANTIGEN; PREDNISONE; TIPIFARNIB; ANTINEOPLASTIC AGENT; NEUROFIBROMIN; QUINOLONE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PATIENT; CASE REPORT; CHILD; CHROMOSOME 17; CYTOFLUOROMETRY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LETTER; LEUKEMIA CELL; NF1 GENE; ONCOGENE; PRE T LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE; GENETICS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CHILD; FEMALE; HUMANS; NEUROFIBROMIN 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; QUINOLONES; SEQUENCE DELETION;

EID: 77954589074     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.81     Document Type: Letter

References (8)

1. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al. Early T-cell precursor leukaemia: a subtype of very highrisk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-156.
2. Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 2008; 452: 764-767. (Pubitemid 351521083)
3. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER et al. Leukemiaassociated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008; 111: 4322-4328.
4. Martinelli G, Iacobucci I, Paolini S, Ottaviani E. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Clin Adv Hematol Oncol 2008; 6: 303-310.
5. Brandwein JM, Leber BF, Howson-Jan K, Schimmer AD, Schuh AC, Gupta V et al. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia 2009; 23: 631-634.
6. Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hählen K et al. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005; 106: 3532-3537. (Pubitemid 41609190)
7. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006; 24: 507-516. (Pubitemid 46630471)
8. Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008; 111: 2589-2596.